The KIF1C Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal cell population derived from the A-549 human lung adenocarcinoma line, engineered for KIF1C gene disruption. This heterogeneous knockout pool enables loss-of-function analysis without single-cell cloning, providing a robust model to study KIF1C-dependent processes in epithelial cells.
A-549 cells, originating from a 58-year-old male lung adenocarcinoma patient, serve as a well-characterized alveolar epithelial model. They retain properties of type II pneumocytes and are extensively used in pulmonary research and lung cancer studies, making them ideal for examining microtubule-based transport, adhesion, and migration.
KIF1C is a plus-end-directed kinesin-3 motor responsible for microtubule-dependent transport of vesicles and protein complexes. It is essential for Golgi ribbon integrity and integrin trafficking to the cell surface. KIF1C interacts with adaptors BICD2 and Hook proteins (HOOK1, HOOK3) and is regulated by Rab6 GTPase. It functions coordinately with the dynein-dynactin complex for bidirectional movement, delivering integrin-containing vesicles and Golgi-derived cargoes, thereby influencing cell adhesion and migration.
In A-549 cells, KIF1C deletion impairs Golgi organization and surface integrin expression, disrupting cell adhesion and migration??processes pivotal in cancer invasion. This knockout model thus serves to elucidate the mechanistic role of KIF1C in lung adenocarcinoma metastatic behavior. Moreover, since KIF1C mutations are linked to spastic paraplegia type 58, the cells provide a non-neuronal platform to study motor protein dysfunction relevant to neurological disorders.
Key applications include western blot validation of knockout, immunofluorescence for Golgi morphology and integrin localization, and functional assays such as scratch wound healing and invasion. Interaction studies via co-immunoprecipitation with BICD2, Rab6, or dynein subunits are feasible, along with live-cell imaging of vesicle dynamics and flow cytometry for surface integrin quantification. Transcriptomic profiling by RNA-seq can reveal downstream pathways. Together, these approaches support research in cancer biology, neurodegeneration, and motor protein pharmacology. For additional information, contact Ascent Research.
